NEUROCRINE BIOSCIENCES INC (NBIX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for NBIX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| NBIX | Director | 64 | ["Financial Expertise / Capital Management and Allocation","Commercial Strategy/Market Access","Healthcare Industry","Biotech and Pharma Operations Expertise","M&A/Business Development Transactions","Governance","Investor Relations","Executive Leadership","Risk Management Oversight"] | ["Audit","Compensation"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ALKS | Director; Chief Executive Officer and Chairman of the Board | 64 | ["Chief Executive Officer of Alkermes, Inc. from February 1991 to April 2007","Chief Executive Officer and President from September 2009 to September 2011","Chairman of the board of directors of the Midsized Biotech Alliance of America","Board member of the Biotechnology Innovation Organization","Board member of the Pharmaceutical Research and Manufacturers of America","Board member of Acceleron Pharma, Inc. from 2004 to December 2019","Board member of Epizyme, Inc. from 2008 to October 2020","Board member of the National Health Council from 2016 to December 2019","Advisory board member of Polaris Venture Partners","Member of the Harvard Medical School Board of Fellows through June 2012","Served on boards of directors of Neurocrine Biosciences, Inc.","Served on boards of directors of Acceleron Pharma, Inc. from 2004 to December 2019","Served on boards of directors of Epizyme, Inc. from 2008 to October 2020","Served on the National Health Council from 2016 to December 2019","Advisory board of Polaris Venture Partners"] | ["Financial Operating","Regulatory Environment Committee","Health Section Governing Board","FDA and Biomedical Research Committee","Financial Operating Committee","MBAA","BIO","PhRMA"] | 2026 |
Biography sourced from the proxy statement filing.
Richard F. Pops has served on the Board of Directors since April 1998. Mr. Pops is the Chairman and Chief Executive Officer of Alkermes plc. He joined Alkermes as Chief Executive Officer in February 1991. Under his leadership, Alkermes has grown from a privately held research-based company with 25 employees to an international, publicly traded pharmaceutical company with more than 2,000 employees. In addition to Alkermes, he currently serves on the Board of Directors of the Biotechnology Innovation Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA). Previously, Mr. Pops served on the Board of Directors of Epizyme, Inc., a biotechnology company focused on epigenetics, and Acceleron Pharma, Inc., a biopharmaceutical company. He holds a B.A. in Economics from Stanford University. The continued service of Mr. Pops to the Company s Board of Directors is based on his leadership experience and track record for growing companies, his strength in business strategy and his financial acumen and capital markets experience. In addition, Mr. Pops is recognized for his service to the biopharmaceutical industry as a member of the Boards of the Biotechnology Innovation Organization and the Pharmaceutical Research and Manufacturers of America. His breadth and range of industry experience from operations and strategy is a significant contribution to the Board of Directors.